메뉴 건너뛰기
JAMA Oncology
Volumn 2, Issue 5, 2016, Pages 571-572
The value of PD-L1 testing in non-small-cell lung cancer
Author keywords

[No Author keywords available]
Indexed keywords

EID: 85010470181     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.0043     Document Type: Short Survey
Times cited : (15)
References (7)
  • 1
    • 84929481480 scopus 로고    scopus 로고
    • Pembrolizumab for the treatment of non-small-cell lung cancer
    • KEYNOTE-001 Investigators
    • Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-2028.
    • (2015) N Engl J Med. , vol.372 , Issue.21 , pp. 2018-2028
    • Garon, E.B.1    Rizvi, N.A.2    Hui, R.3
  • 2
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
    • (2015) N Engl J Med. , vol.373 , Issue.2 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3
  • 3
    • 84944937210 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-1639.
    • (2015) N Engl J Med. , vol.373 , Issue.17 , pp. 1627-1639
    • Borghaei, H.1    Paz-Ares, L.2    Horn, L.3
  • 4
    • 84950117835 scopus 로고    scopus 로고
    • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial
    • Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015;S0140-6736(15)01281-7.
    • (2015) Lancet
    • Herbst, R.S.1    Baas, P.2    Kim, D.W.3
  • 5
    • 84975643096 scopus 로고    scopus 로고
    • Predictive biomarkers for checkpoints, first tests approved
    • Garber K. Predictive biomarkers for checkpoints, first tests approved. Nat Biotechnol. 2015;33(12):1217-1218.
    • (2015) Nat Biotechnol , vol.33 , Issue.12 , pp. 1217-1218
    • Garber, K.1
  • 6
    • 84906903314 scopus 로고    scopus 로고
    • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial
    • Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-673.
    • (2014) Lancet , vol.384 , Issue.9944 , pp. 665-673
    • Garon, E.B.1    Ciuleanu, T.E.2    Arrieta, O.3
  • 7
    • 84933554760 scopus 로고    scopus 로고
    • Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) vs IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
    • Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) vs IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol. 2015;33(suppl):abstr LBA1.
    • (2015) J Clin Oncol. , vol.33
    • Wolchok, J.D.1    Chiarion-Sileni, V.2    Gonzalez, R.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.